Neuropsychiatric Disorders Treatment Companies

Eleusis Therapeutics (US) Received Breakthrough Therapy Designation from the FDA for its ketamine-based treatment for major depressive disorder, accelerating the development process. Entered into a strategic partnership with Otsuka Pharmaceutical Co. Ltd. for the global development and commercialization of its lead candidate.

Compass Pathways (UK) Announced positive Phase 2b results for psilocybin therapy in treatment-resistant depression, demonstrating significant improvements in patients' symptoms. Partnering with leading academic institutions to explore the use of psychedelic medicines for other mental health conditions like anxiety and addiction.

Roche (Switzerland) Launched Vraylar® (cariprazine) for bipolar depression in the US, offering a new treatment option with a different mechanism of action compared to traditional antidepressants. Invested in research and development of antipsychotic medications with neurodegenerative disease prevention potential.

Johnson & Johnson (US) Completed the acquisition of Akili, a digital health company developing video game-based therapeutics for ADHD and other neuropsychiatric disorders. Announced plans to expand its Janssen Neuroscience division with a focus on developing innovative therapies and digital solutions for brain health.

• AstraZeneca (U.K.)


• GlaxoSmithKline (U.K.)


• Universal Health Services Inc. (U.S.)


• Biogen (U.S.)


• Boehringer Ingelheim GmbH (Germany)


• Eli Lilly (U.S.)


• Bristol-Meyer Squibb (U.S.)


• Johnson & Johnson (U.S.)


• Pfizer (U.S.)


• Wyeth (U.S.)


• Otsuka Holdings Co. Ltd (Japan)


• Astellas Pharma Inc. (Japan)